NexImmune, Inc. (NEXI)
| Market Cap | 28.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.38M |
| Shares Out | 24.16M |
| EPS (ttm) | -2.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,158 |
| Open | 1.21 |
| Previous Close | 1.25 |
| Day's Range | 1.16 - 1.21 |
| 52-Week Range | 1.08 - 18.78 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 3.57 (+207.8%) |
| Earnings Date | Aug 8, 2022 |
About NEXI
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that ... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for NEXI stock is "Buy." The 12-month stock price forecast is 3.57, which is an increase of 207.76% from the latest price.
News
NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Trea...
GAITHERSBURG, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug
NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.
Why Is NexImmune (NEXI) Stock Up 30% Today?
NexImmune appears to be making headway in the company's ongoing battle against HPV-related cancers -- and NEXI stock is heading higher today. The post Why Is NexImmune (NEXI) Stock Up 30% Today?
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers
GAITHERSBURG, Md., July 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
What Makes NexImmune, Inc. (NEXI) a New Buy Stock
NexImmune, Inc. (NEXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates
GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes
GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), Yale and JDRF have begun a two-year project to explore the use of NexImmune's AIM nanoparticles in combination with an...
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors
GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...
NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center's Herbert Irvin...
GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer
Dr. Oelke is a scientific co-founder of NexImmune and a pioneer in the field of artificial antigen presenting cell (aAPC) technology Dr. Oelke is a scientific co-founder of NexImmune and a pioneer in th...
Executives Buy More Than $1M Of 5 Penny Stocks
The Dow Jones jumped around 200 points on Tuesday. Investors, meanwhile, focused on some notable insider trades.
Insiders Buying These 5 Penny Stocks
The Dow Jones surged around 350 points on Thursday. Investors, meanwhile, focused on some notable insider trades.
NexImmune, Zephyr Join Forces For Oncology Target Discovery, Validation
NexImmune Inc (NASDAQ: NEXI) and Zephyr AI have announced a strategic partnership focusing on discovering and validating novel targets for new T-cell-mediated therapies in oncology. The collaboration w...
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel targ...
NexImmune Announces Melanoma Research Collaboration with NYU Langone's Perlmutter Cancer Center
GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune to Present at the Barclays 2022 Global Healthcare Conference
GAITHERSBURG, Md., March 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
NexImmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...
NexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors
Ms. Jones, a veteran of the biotechnology and pharmaceutical industries, has served as an Executive Officer of NexImmune since 2017 Ms. Jones, a veteran of the biotechnology and pharmaceutical industrie...
NexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrin...
GAITHERSBURG, Md., Feb. 01, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expandi...
GAITHERSBURG, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board
GAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
GAITHERSBURG, Md., Dec. 12, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune Reports Third Quarter 2021 Financial Results and Provides Business Updates
GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune to Announce Third Quarter 2021 Financial Results and Provide Corporate Update on November 12, 2021
GAITHERSBURG, Md., Nov. 08, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...
NexImmune to Present at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targete...